Trial reportEuropean stroke journal2026
MRI measurement of the delayed secondary ischaemic injury following endovascular thrombectomy: results from the REPERFUSE-NA1 study.
Trial report in European stroke journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02930018 (A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundBrain injury due to stroke is an important determinant of long-term disability. The acute lesion visible on MRI with DWI underestimates the total burden of the ischaemic injury. The objectives of this study are: (1) quantify the delayed secondary ischaemic injury volume by calculating the whole and regional brain volume loss at 90-days post-stroke and (2) determine whether brain volume loss independently predicted functional outcome at 90 days.
methodsREPERFUSE-NA1 is a prospective, multisite MRI sub-study of the ESCAPE-NA1 trial (ClinicalTrialGov #NCT02930018), which randomised participants receiving endovascular therapy (EVT) to nerinetide versus placebo. MRI was acquired immediately after therapy (day 1, <5 hours post-EVT) and at 90-days. The primary outcome was change in whole-brain volume between day 1 and 90. Serial MR metrics were used to generate sample size calculations for future neuroprotectant trials.
resultsA total of 43 patients of mean age 65.1 years (SD = 14.9, 51.2% female, median NIHSS 15 [Q1-Q3 = 11-20]) were included. In the entire cohort, there was significant whole-brain volume loss (P < .001), ventricular enlargement (P < .001), and cortical grey matter (P = .001), subcortical white matter (P < .001), thalamic (P < .001), and hippocampal (P < .001) volume loss in the ipsilateral hemisphere. Baseline DWI volume and ipsilateral hemispheric brain atrophy were significant predictors of functional independence, with P-values of < .001. There was no significant association between nerinetide treatment and volume changes at 90-days. For a prospective 90-day neuroprotectant trial to demonstrate 50% reduction, 41 patients per group would be needed using ventricular volume change.
conclusionThis study indicates that whole-brain volume loss is a feasible measurement of delayed secondary ischaemic injury. Future neuroprotectant clinical trials could utilise MR-based markers of delayed ischaemic injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.